The Role of Apolipoproteins in the Commonest Cancers: A Review

Simple Summary Apolipoproteins (APOs) are crucial components in our blood that are responsible for fat management. Recent scientific discoveries suggest a provocative link between APOs and a range of cancers, including, but not limited to, breast, lung, and prostate cancer. The specific role of some APOs in causing cancer remains enigmatic. In this review, we summarize evidence from the literature supporting the potential involvement of APOs in the onset of cancer. We also highlight promising avenues for treatment through the inhibition of APOs.Abstract Apolipoproteins (APOs) are vital structural components of plasma lipoproteins that are involved in lipid metabolism and transport. Recent studies have reported an association between apolipoprotein dysregulation and the onset of a variety of human cancers; however, the role of certain APOs in cancer development remains unknown. Based on recent work, we hypothesize that APOs might be involved in the onset of cancer, with a focus on the most common cancers, including breast, lung, gynecological, colorectal, thyroid, gastric, pancreatic, hepatic, and prostate cancers. This review will focus on the evidence supporting this hypothesis, the mechanisms linking APOs to the onset of cancer, and the potential clinical relevance of its various inhibitors.

Automated summary

Apolipoproteins (APOs) are important components in blood responsible for fat management. Recent discoveries suggest a potential link between APOs and various cancers, though the specific role of certain APOs remains unknown. This review summarizes evidence supporting the involvement of APOs in cancer onset and explores the potential clinical significance of inhibiting APOs.